Assessing the Prevalence of Latent Tuberculosis Infection in Healthy and Immunocompromised Individuals in Dutsin-Ma Metropolis, Katsina State, Nigeria A Cross-Sectional Study

doi:https://doi.org/10.5281/zenodo.15777259

Biomedicine and Chemical Sciences

2024, Volume 3, Issue 4 : 159-164 doi: https://doi.org/10.5281/zenodo.15777259

Research Article

Assessing the Prevalence of Latent Tuberculosis Infection in Healthy and Immunocompromised Individuals in Dutsin-Ma Metropolis, Katsina State, Nigeria A Cross-Sectional Study

Ignatius Mzungu

Vivian Veren Tyough

Emmanuel Dayo Alabi

DOI : https://doi.org/10.5281/zenodo.15777259

Received

Jan. 26, 2024

Revised

Sept. 20, 2024

Accepted

Sept. 25, 2024

Published

Oct. 1, 2024

Abstract

Latent Tuberculosis Infection (LTBI) is a widespread condition affecting a significant portion of the global population. People with LTBI have a 5-10% chance of developing active Tuberculosis (TB) during their lifetime. However, there is a shortage of data on the prevalence of LTBI in healthy and immunocompromised individuals in the Dutsin-Ma metropolis. Identifying and treating LTBI is crucial for reducing the burden of TB globally. This cross-sectional study aimed to determine the prevalence of LTBI in healthy and immunocompromised patients in the Dutsin-Ma, Katsina State, Nigeria. 170 blood samples were randomly collected from participants across three (3) healthcare facilities in Dutsin-Ma in September 2023 and screened for anti-TB antibodies using the Rapid Tuberculosis Test Card™ (RTTC); 50 were healthy participants, 65 were pregnant women, 30 were HIV-positive patients, and 25 were diabetic patients. The sociodemographic data were collected and analyzed using descriptive statistics and Chi-square to test for association. Among the 170 participants tested, 12.94 % (22/170) were serologically positive for anti-TB antibodies. Several risk factors associated with LTBI were identified. However, statistically, there was not enough evidence to conclude that any of the risk factors are significantly associated with the prevalence of LTBI at 95% CI and a P-value of ≤ 0.05 in this survey. The study highlights the need for routine screening and treatment of LTBI in both healthy and immunocompromised individuals in the study locality. This is vital in reducing the global burden of LTBI and active TB infections.

Keywords

Diabetes mellitus

Dutsin-Ma

Human immunodeficiency virus

Immunocompromised

Latent tuberculosis

Rapid tuberculosis test card

REFERENCES

Akinshipe, B. O., Yusuf, E. O., Akinshipe, F. O., Moronkeji, M. A., & Nwaobi, A. C. (2019). Prevalence and determinants of pre-diabetes and latent tuberculosis infection among apparently healthy adults in three communities in Southern Nigeria. International Journal of Immunology, 7(2), 23-32.
Alene, K. A., Viney, K., Moore, H. C., Wagaw, M., & Clements, A. C. (2019). Spatial patterns of tuberculosis and HIV co-infection in Ethiopia. PloS one, 14(12), e0226127. https://doi.org/10.1371/journal.pone.0226127
Al-Rifai, R. H., Pearson, F., Critchley, J. A., & Abu-Raddad, L. J. (2017). Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. PloS one, 12(11), e0187967. https://doi.org/10.1371/journal.pone.0187967
Bloom, B. R., & Murray, C. J. (1992). Tuberculosis: commentary on a reemergent killer. Science, 257(5073), 1055-1064. https://doi.org/10.1126/science.257.5073.1055
Chen, Z., Wang, T., Du, J., Sun, L., Wang, G., Ni, R., ... & Gong, W. (2025). Decoding the WHO Global Tuberculosis Report 2024: A Critical Analysis of Global and Chinese Key Data. Zoonoses, 5(1), 999. https://doi.org/10.15212/ZOONOSES-2024-0061
Chukwudi, U. K., Chuka, E. P., & MaryAnn, O. N. (2020). Interferon gamma release assay of latent tuberculosis infection amongst prisoners in Anambra State. IOSR Journal of Dental and Medical Sciences, 19, 10:11. https://doi.org/10.9790/0853-1910110715
Churchyard, G. J., Scano, F., Grant, A. D., & Chaisson, R. E. (2007). Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. The Journal of infectious diseases, 196(Supplement_1), S52-S62. https://doi.org/10.1086/518662
Corbett, E. L., Marston, B., Churchyard, G. J., & De Cock, K. M. (2006). Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. The Lancet, 367(9514), 926-937. https://doi.org/10.1016/S0140-6736(06)68383-9
Dixon, B. (2007). Diabetes and tuberculosis: an unhealthy partnership. The Lancet Infectious Diseases, 7(7), 444. https://doi.org/10.1016/S1473-3099(07)70144-5
Firănescu, A. G., Popa, A., Sandu, M. M., Protasiewicz, D. C., Popa, S. G., & Moță, M. (2016). The global prevalence and incidence of diabetes mellitus and pulmonary tuberculosis. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 23(3), 319-326.
Gazette, N. O. (2009). Nigeria census final results. Official Gazette, National Population Commission Federal Republic of Nigeria.
Gounder, C., de Queiroz Mello, F. C., Conde, M. B., Bishai, W. R., Kritski, A. L., Chaisson, R. E., & Dorman, S. E. (2002). Field evaluation of a rapid immunochromatographic test for tuberculosis. Journal of clinical microbiology, 40(6), 1989-1993. https://doi.org/10.1128/jcm.40.6.1989-1993.2002
Harries, A. D., Satyanarayana, S., Kumar, A. M. V., Nagaraja, S. B., Isaakidis, P., Malhotra, S., ... & Kapur, A. (2013). Epidemiology and interaction of diabetes mellitus and tuberculosis and challenges for care: a review. Public health Action, 3(1), 3-9. https://doi.org/10.5588/pha.13.0024
Hino, Y., Eshima, N., Tokumaru, O., Bacal, K., Tanaka, Y., Karukaya, S., & Yamashita, Y. (2022). A change in the timing of the Bacillus Calmette–Guérin vaccination in 2013 was associated with an increase in the incidence rate of infants with latent tuberculosis infection. Journal of Infection and Chemotherapy, 28(7), 929-933. https://doi.org/10.1016/j.jiac.2022.03.018
Lyashchenko, K. P., Singh, M., Colangeli, R., & Gennaro, M. L. (2000). A multi-antigen print immunoassay for the development of serological diagnosis of infectious diseases. Journal of immunological methods, 242(1-2), 91-100. https://doi.org/10.1016/S0022-1759(00)00241-6
Migliori, G. B., Ong, C. W., Petrone, L., D'Ambrosio, L., Centis, R., & Goletti, D. (2021). The definition of tuberculosis infection based on the spectrum of tuberculosis disease. Breathe, 17(3). https://doi.org/10.1183/20734735.0079-2021
Morrison, J., Pai, M., & Hopewell, P. C. (2008). Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. The Lancet infectious diseases, 8(6), 359-368. https://doi.org/10.1016/S1473-3099(08)70071-9
Orazulike, N. C., Alegbeleye, J. O., Obiorah, C. C., Nyengidiki, T. K., & Uzoigwe, S. A. (2017). A 3-year retrospective review of mortality in women of reproductive age in a tertiary health facility in Port Harcourt, Nigeria. International journal of women's health, 769-775. https://doi.org/10.2147/IJWH.S138052
Pesanti, E. L. (1994). The negative tuberculin test. Tuberculin, HIV, and anergy panels. American journal of respiratory and critical care medicine, 149(6), 1699-1709. https://doi.org/10.1164/ajrccm.149.6.7710481
Raviglione, M. (2006). XDR-TB: entering the post-antibiotic era?. The International Journal of Tuberculosis and Lung Disease, 10(11), 1185-1187.
Say, L., Chou, D., Gemmill, A., Tunçalp, Ö., Moller, A. B., Daniels, J., ... & Alkema, L. (2014). Global causes of maternal death: a WHO systematic analysis. The Lancet global health, 2(6), e323-e333. https://doi.org/10.1016/S2214-109X(14)70227-X
Van Rie, A., & Enarson, D. (2006). XDR tuberculosis: an indicator of public-health negligence. The Lancet, 368(9547), 1554-1556. https://doi.org/10.1016/S0140-6736(06)69575-5
Vynnycky, E., & Fine, P. E. (2000). Lifetime risks, incubation period, and serial interval of tuberculosis. American journal of epidemiology, 152(3), 247-263. https://doi.org/10.1093/aje/152.3.247
World Health Organization. (2022). Global tuberculosis report 2021: supplementary material. World Health Organization.
World Health Organization. (2024). WHO operational handbook on tuberculosis. Module 1: prevention-tuberculosis preventive treatment. World Health Organization.

Recommended Articles

Research Article Open Access

Design and Synthesis Ligands Tetradents Substituted with Halogenes in α- Position and Conjugation with Riboflavin (Bioconjugates)

Nasser Thallaj

2022, Volume 1, Issue 2 : 47-56

DOI: https://doi.org/10.48112/bcs.v1i2.85

Download PDF

Research Article Open Access

Identification of Pathogenic Fungi in Renal Transplant Patients by Conventional and Molecular Methods

Faheema Jabbar ,

Azhar A.Al-Attraqchi ,

Dina Nabeel Alkhayyat

2022, Volume 1, Issue 3 : 126-131

DOI: https://doi.org/10.48112/bcs.v1i3.198

Download PDF

Research Article Open Access

Synthesis, Characterization and Analytical Studies of Three Newly Schiff Bases As A New Anti-Human Breast Cancer (MCF-7)

Mustafa M. Grafa ,

Hanan M. Ali

2022, Volume 1, Issue 3 : 168-177

DOI: https://doi.org/10.48112/bcs.v1i3.127

Download PDF

Research Article Open Access

Spectroscopic and Thermal Studies of Some Palladium(II) Complexes with 2-amino-4-(4-subsistuted phenyl)thiazole Derivatives

Thaaer K. Maki AL-Jaffer ,

Zeki O Naser ,

Ali Jameel Hameed

2022, Volume 1, Issue 2 : 78-82

DOI: https://doi.org/10.48112/bcs.v1i2.104

Download PDF

Biomedicine and Chemical Sciences journal thumbnail

Volume 3, Issue 4

Downloads

Download PDF xml

Download XML

Citations

2 Views

1 Downloads

Share this article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.

Biomed. Chem. Sci. open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.